INITIO Medical has earned recognition from the International Centers for Precision Oncology Foundation (ICPO) as the first ICPO Theranostics Clinical Center of Excellence in Canada and the wider North American region. The distinction highlights INITIO’s dedication to advancing theranostic medicine and delivering patient-focused, high-standard care.
Health Technology Insights: Eleanor Health Joins Cigna and Evernorth Networks
Odile Jaume, CEO of the ICPO Foundation, celebrated INITIO’s Burnaby‑Vancouver Theranostics Center as its newest addition to the ICPO network. She remarked that this accreditation—based on international protocols from SNMMI, EANM, ENETS, and IAEA—sets a benchmark for clinical excellence in theranostics across North America. The honor was formally bestowed to Dr. Philip Cohen and Mina Bechai during a certification ceremony in Barcelona on October 4, 2025, just before the EANM annual meeting. Jaume also emphasized plans for collaboration via ICPO Academy training and onsite education at INITIO to broaden patient access to theranostic therapy in Canada and beyond.
Mina Bechai, Founder and CEO of INITIO Medical, said this recognition validates the team’s commitment to precision oncology. She expressed pride in being the first in North America to gain ICPO accreditation and emphasized eagerness to work with the ICPO Foundation in expanding access to theranostic treatments and improving patient outcomes.
Health Technology Insights: Halozyme to Acquire Elektrofi for Drug Delivery Expansion
Dr. Francois Lamoureux, President of the Canadian Association of Nuclear Medicine (CANM), added that this achievement is a milestone for Canadian nuclear medicine expertise. He believes this will spur further progress in theranostics and help guarantee that Canadian patients receive cutting‑edge nuclear medicine services.
Health Technology Insights: Biocon Sets U.S. Launch Date for Denosumab Biosimilars
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
